Spyre Therapeutics's total assets for Q3 2024 were $421.09M, a decrease of -3.43% from the previous quarter. SYRE total liabilities were $93.70M for the fiscal quarter, a 51.91% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.